^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD20 positive

    i
    Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
    Entrez ID:
    494216
    Related biomarkers:
    Expression
    Others
    4d
    Potential role of 68Ga- and 177Lu-cyclic pentapeptides for in-vivo targeting CXCR4 receptor expression in chemotherapy relapse MCL patient. (PubMed, Asia Ocean J Nucl Med Biol)
    The avidity of both 68Ga- and 177Lu- cyclic pentapeptide radiotracers was noted in the mesenteric mass at the L4 level. Dosimetry study using 177Lu-cyclic pentapeptide indicated kidneys as the critical organ with max residence time of 5.39 h. Theragnostic complex of radiolabelled 68Ga/177Lu- cyclic pentapeptides have the potential to in-vivo target the CXCR4 receptor expression.
    Preclinical • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD79B (CD79b Molecule)
    |
    CD20 positive
    4d
    An Intestinal Intravascular Large B-Cell Lymphoma Presenting as Small Bowel Ischemia: A Case Report and Literature Review. (PubMed, Cureus)
    The patient was transferred to the hematology department to initiate chemotherapy with the R-CHOP regimen...Intestinal IVLBCL, a rare malignant lymphoma characterized by the selective proliferation of tumor cells within the lumen of small- to medium-sized blood vessels, represents a GI manifestation of IVLBCL. This case report describes a 78-year-old man who presented with vomiting and abdominal pain and was diagnosed with IVLBCL.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab)
    5d
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=150 --> 90
    Enrollment change
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • TQB2825
    6d
    Bendamustine combined with Zuberitamab (BZ) followed by Orelabrutinib combined with Zuberitamab (OZ) in the treatment of newly diagnosed marginal zone lymphoma:A Phase II prospective clinical study (ChiCTR2500115104)
    P=N/A, N=74, Not yet recruiting, The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib) • bendamustine • Anruixi (zuberitamab)
    6d
    A prospective observational study of Orelabrutinib combined with anti-CD20 monoclonal antibody followed by Orelabrutinib maintenance as first-line treatment for MZ (ChiCTR2500113665)
    P=N/A, N=40, Not yet recruiting, The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib)
    6d
    A prospective, multicenter, cocohort controlled clinical trial on the efficacy and safety of chidamide in maintenance treatment for newly diagnosed high-risk diffuse large B-cell lymphoma (ChiCTR2500112540)
    P=N/A, N=204, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epidaza (chidamide)
    6d
    A prospective, single-arm, multicenter clinical study of zanubrutinib in combination with obinutuzumab and low-dose bendamustine as first-line treatment for high-risk (FLIPI-2 >= 3) follicular lymphoma patients. (ChiCTR2500114118)
    P4, N=25, Not yet recruiting, People‘s Hospital of Xinjiang Uygur Autonomous Region; People‘s Hospital of Xinjiang Uygur Autonomous Region
    New P4 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • bendamustine
    6d
    Rituximab, Lenalidomide, and Orelabrutinib Combination Regimen in the Treatment of marginal zone cell lymphoma: a Prospective, Single-Arm, Phase II Clinical Study (ChiCTR2500115204)
    P2, N=46, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    6d
    Immuno and targeted therapy for Richter transformation to diffuse large B-cell lymphoma (ChiCTR2500109894)
    P2, N=34, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1)
    |
    CD20 positive
    |
    lenalidomide • Tevimbra (tislelizumab-jsgr) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Columvi (glofitamab-gxbm)
    7d
    A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=3, Completed, Peking University | Recruiting --> Completed | N=18 --> 3
    Trial completion • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    8d
    A case of marginal zone lymphoma presenting with paraneoplastic vasculitis and pulmonary infiltration. (PubMed, Respir Med Case Rep)
    Rituximab monotherapy was initiated, resulting in both clinical and radiological improvement. This case highlights the importance of considering underlying malignancy in patients with unexplained systemic inflammation, vasculitic skin lesions, or cytopenias, particularly when autoimmune markers are negative. Prompt histological diagnosis and multidisciplinary collaboration enabled timely immunochemotherapy, resulting in the resolution of both lymphoma and associated paraneoplastic complications.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab)
    8d
    Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • carfilzomib • Truxima (rituximab-abbs)